Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 1;35(3):278-285.
doi: 10.1097/WCO.0000000000001067.

MRI and laboratory monitoring of disease-modifying therapy efficacy and risks

Michael Barnett  1   2 , Yael Barnett  2   3 , Stephen Reddel  1   4
Affiliations
Review

MRI and laboratory monitoring of disease-modifying therapy efficacy and risks

Michael Barnett et al. Curr Opin Neurol. .

Abstract

Purpose of review: Increasingly, therapeutic strategy in multiple sclerosis (MS) is informed by imaging and laboratory biomarkers, in addition to traditional clinical factors. Here, we review aspects of monitoring the efficacy and risks of disease-modifying therapy (DMT) with both conventional and emerging MRI and laboratory measures.

Recent findings: The adoption of consensus-driven, stable MRI acquisition protocols and artificial intelligence-based, quantitative image analysis is heralding an era of precision monitoring of DMT efficacy. New MRI measures of compartmentalized inflammation, neuro-degeneration and repair complement traditional metrics but require validation before use in individual patients. Laboratory markers of brain cellular injury, such as neurofilament light, are robust outcomes in DMT efficacy trials; their use in clinical practice is being refined. DMT-specific laboratory monitoring for safety is critical and may include lymphocytes, immunoglobulins, autoimmunity surveillance, John Cunningham virus serology and COVID-19 vaccination seroresponse.

Summary: A biomarker-enhanced monitoring strategy has immediate clinical application, with growing evidence of long-term reductions in disability accrual when both clinically symptomatic and asymptomatic inflammatory activity is fully suppressed; and amelioration of the risks associated with therapy. Emerging MRI and blood-based measures will also become important tools for monitoring agents that target the innate immune system and promote neuro-repair.

PubMed Disclaimer

References

    1. Calabresi PA, Kappos L, Giovannoni G, et al. Measuring treatment response to advance precision medicine for multiple sclerosis. Ann Clin Transl Neurol 2021; 8:2166–2173.
    1. Sormani MP, Freedman MS, Aldridge J, et al. MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. Mult Scler Relat Disord 2021; 49:102790.
    1. Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 2019; 76:536–541.
    1. Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321:175–187.
    1. Lu G, Beadnall HN, Barton J, et al. The evolution of ‘no evidence of disease activity’ in multiple sclerosis. Mult Scler Relat Disord 2018; 20:231–238.